EUVIMEDEUVIMED entdecken
Crossref

Visible tumor-targeting biohybrid vehicles reprogram cancer-associated fibroblasts to potentiate photothermal immunotherapy

Limin Jin, Xiaohan Yang, Yan Zhang, Xin Meng, Pengyu Huang, Lin Mei, Dunwan Zhu, Xia Dong, Feng Lv

Acta Biomaterialia · 2026-03 · 213 · 579-593

DOI: 10.1016/j.actbio.2026.02.018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2026-03. Verfasst von Limin Jin und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Na…. Hauptthemen laut MEDLINE: Immunotherapy, Photothermal Therapy, Cancer-Associated Fibroblasts, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Tianjin Municipal Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The extracellular matrix (ECM) is a physical barrier that severely hinders the deep penetration of photothermal agents and immune cells, which is a major challenge to the efficacy of tumor photothermal immunotherapy. In this study, a visible tumor-targeting platelet membrane-wrapped biohybrid vehicle was developed to potentiate photothermalimmunotherapy through cancer-associated fibroblasts (CAFs) reprogramming. This system integrated IR820-modified platelet membrane and manganese-polyphenol nanoparticlesloaded with losartan. Based on the image contrast signals from IR820 and manganese ions, the biohybrid system enabled visual delivery under the guidance of fluorescence-magnetic dual-modal imaging. After reprogramming CAFs to a quiescent state with released losartan, the ECM was remodeled. The attenuated physical barrier and platelet carriers collectively facilitated the deep penetration of photothermal agents, improving the sensitivity of photothermal therapy. Moreover, the synergistic strategy of photothermal stimulation and CAFs regulation simultaneously activated the systemic immunity and alleviated the immunosuppressive tumor microenvironment. The biohybrid delivery system effectively reconstructed the anti-tumor immune defense system to boost the efficacy of photothermal immunotherapy through a positive feedback mechanism. STATEMENT OF SIGNIFICANCE: The dense extracellular matrix (ECM) constitutes a major physical barrier that severely restricts the penetration of photothermal agents and immune cells into tumors, thereby substantially limiting the efficacy of photothermal immunotherapy. A key cause of this barrier is cancer-associated fibroblasts (CAFs), which also suppress immunity. Reverting CAFs to a quiescent state or reprogramming them toward a tumor-suppressive phenotype offers a promising strategy to ameliorate ECM deposition and reverse immunosuppression. A visible tumor-targeting platelet membrane-wrapped biohybrid vehicle was developed to potentiate photothermal-immunotherapy through CAFs reprogramming. This intervention disrupts the stromal barrier and mitigates immune suppression for boosting anti-tumor immunity. Furthermore, the system enables real-time, dual-modal MRI-fluorescence imaging, providing a visual guidance platform for precision photothermal immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyPhotothermal TherapyCancer-Associated FibroblastsNeoplasmsAnimalsHumansCell Line, TumorMiceNanoparticlesBlood PlateletsTumor MicroenvironmentMice, Inbred BALB C

Stichwörter der Autor:innen

Biohybrid systemCancer-associated fibroblastsImaging guidancePhotothermal immunotherapyTargeted delivery

Autor:innen und Institutionen

  • State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Enginee…

Förderung

  • National Natural Science Foundation of China
  • Tianjin Municipal Natural Science Foundation

Zitieren

APA

Jin, L., Yang, X., Zhang, Y., Meng, X., Huang, P., Mei, L., Zhu, D., Dong, X., & Lv, F. (2026). Visible tumor-targeting biohybrid vehicles reprogram cancer-associated fibroblasts to potentiate photothermal immunotherapy. Acta Biomaterialia, 213, 579-593. https://doi.org/10.1016/j.actbio.2026.02.018

Vancouver

Jin L, Yang X, Zhang Y, Meng X, Huang P, Mei L, et al. Visible tumor-targeting biohybrid vehicles reprogram cancer-associated fibroblasts to potentiate photothermal immunotherapy. Acta Biomaterialia. 2026;213:579-593. doi:10.1016/j.actbio.2026.02.018

BibTeX
@article{Jin2026,
  author = {Jin, Limin and Yang, Xiaohan and Zhang, Yan and Meng, Xin and Huang, Pengyu and Mei, Lin and Zhu, Dunwan and Dong, Xia and Lv, Feng},
  title = {Visible tumor-targeting biohybrid vehicles reprogram cancer-associated fibroblasts to potentiate photothermal immunotherapy},
  journal = {Acta Biomaterialia},
  year = {2026},
  volume = {213},
  pages = {579--593},
  doi = {10.1016/j.actbio.2026.02.018}
}
Kostenlos starten →